Acciones Luye Pharma Group Ltd Singapore S.E.
Acciones
LUYE
BMG5722Z1014
Farmacéuticos
Ventas 2024 * | 6830,64 M 940 M 1274,26 M 878 M | Ventas 2025 * | 7811,02 M 1074,91 M 1457,15 M 1003,93 M | Capitalización | 9452,34 M 1300,77 M 1763,33 M 1214,89 M |
---|---|---|---|---|---|
Resultado Neto 2024 * | 677 M 93,16 M 126 M 87,01 M | Resultado Neto 2025 * | 965 M 133 M 180 M 124 M | VE / Ventas 2024 * | 1,76 x |
Deuda neta 2024 * | 2592,37 M 357 M 484 M 333 M | Deuda neta 2025 * | 2409,63 M 332 M 450 M 310 M | VE / Ventas 2025 * | 1,52 x |
P/E ratio 2024 * |
14,7
x | P/E ratio 2025 * |
11,1
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 51,84 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 02/07/03 |
Rong Bing Yang
PSD | President | 58 | 08/06/94 |
Yun Li Xue
PRN | Corporate Officer/Principal | 60 | 08/06/94 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Hui Xian Yuan
BRD | Director/Board Member | 65 | 08/06/94 |
Rong Bing Yang
PSD | President | 58 | 08/06/94 |
Dian Bo Liu
CEO | Chief Executive Officer | 59 | 02/07/03 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+55,32 % | 815 mil M | |
+44,05 % | 641 mil M | |
-6,75 % | 352 mil M | |
+13,56 % | 314 mil M | |
+10,68 % | 303 mil M | |
+16,57 % | 242 mil M | |
+13,31 % | 218 mil M | |
+8,48 % | 168 mil M | |
-2,81 % | 159 mil M |